Aytu BioPharma, Inc. (AYTU) News
Track canonical SquawkNews coverage tagged to AYTU, Aytu BioPharma, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Aytu BioPharma Is Maintained at Buy by Ascendiant Capital
Ratings actions from Benzinga: GMT) Aytu BioPharma Price Target Raised to $15.00/Share From $14.50 by Ascendiant CapitalRatings actions from Benzinga
NEWS | Sep 30, 2026, 10:06 AM UTC
L
Ascendiant Capital maintains Buy rating on Aytu BioPharma, $15 price target
Ascendiant Capital maintained their Buy rating on Aytu BioPharma's stock with a price target of $15.00.The price target implies an upside of 581.8% from the Sep 29 close of $2.20.Key takeaways from the analyst noteStrong
EARNINGS | Sep 30, 2026, 09:56 AM UTC
L
Weekly Recap: FY26 loss and Consumer Health sale, U.S. mfg move
Aytu BioPharma, Inc. (NASDAQ:AYTU) reported fiscal 2026 revenue of $57.57M and a $14.25M net loss while reshaping its business—selling Consumer Health, winding down non—core trials and shifting Adzenys/Cotempla manufactu
EARNINGS | Sep 28, 2026, 11:04 AM UTC
H
Transcript: Aytu BioPharma Q4 2026 Earnings Conference Call
On Tuesday, Aytu BioPharma (NASDAQ: AYTU ) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you APIs. For real-time access to our e
LIVE | Sep 22, 2026, 09:16 PM UTC
M
Aytu BioPharma Q4 revenue beats estimates on EXXUA sales
EQUITY | Sep 22, 2026, 08:18 PM UTC
M
Aytu BioPharma reports FY2026 revenue $57.6M and Q4 $16.1M
FY2026 net revenue fell to $57.6M from $66.4M, while Q4 net revenue rose to $16.1M (+6.4% YoY). Fourth-quarter Adjusted EBITDA was $0.5M; full-year Adjusted EBITDA was a loss.
EQUITY | Sep 22, 2026, 08:14 PM UTC
L
AYTU - Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
AYTU - Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
EARNINGS | Sep 22, 2026, 08:05 PM UTC
L
AYTU - Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
AYTU - Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
EARNINGS | Sep 16, 2026, 08:30 PM UTC
M
AYTU Terminates Metadate Agreement
Aytu BioPharma terminates Metadate agreement with Lannett effective June 23, 2026
EQUITY | Jun 25, 2026, 08:40 PM UTC